Binding activities of cis-platin-damage-recognition proteins in human tumour cell lines.
Proteins can be detected by South-western analyses of human tumour-cell extracts binding to double-stranded oligonucleotide DNA treated in vitro with the chemotherapeutic drug cis-diamminedichloroplatinum (II) (CDDP), but not to untreated DNA. The relative molecular masses of proteins binding to the CDDP-treated double-stranded oligonucleotide are 25, 48 and 97 kDa. The binding activity of 2 of the CDDP-damage-recognition proteins, of relative molecular mass 48 and 97 kDa, is greater in a CDDP-resistant human ovarian tumour cell line than in the parental sensitive line. South-western analysis of a panel of human bladder cell lines and CDDP-sensitive testicular cell lines show consistent patterns of CDDP-damage-recognition proteins within each cell type, however with differences between the 2 cell types. Binding of the proteins to CDDP-damaged DNA and the altered binding activity detected in tumour cell lines suggests that alteration in damage-recognition proteins could play a role in tumour response to CDDP.
McLaughlin
K
K
CRC Department of Medical Oncology, Beatson Laboratories, Glasgow, UK.
Coren
G
G
Masters
J
J
Brown
R
R
D001483:Base Sequence; D002945:Cisplatin / Q000378:metabolism*; D004249:DNA Damage; D004260:DNA Repair; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006609:High Mobility Group Proteins / Q000378:metabolism*; D006801:Humans; D066298:In Vitro Techniques; D008297:Male; D008969:Molecular Sequence Data; D009838:Oligodeoxyribonucleotides / Q000737:chemistry; D013736:Testicular Neoplasms / Q000378:metabolism / Q000473:pathology; D035602:Transcriptional Elongation Factors; D014407:Tumor Cells, Cultured; D001749:Urinary Bladder Neoplasms / Q000378:metabolism / Q000473:pathology
D004268:DNA-Binding Proteins; D006609:High Mobility Group Proteins; D009838:Oligodeoxyribonucleotides; C073537:SSRP1 protein, human; D035602:Transcriptional Elongation Factors; D002945:Cisplatin